SIREN : 828879759
FINANCIERE ELAVA PHARMA is a French company founded 9 years ago, specialized in the sector Activités des sièges sociaux. Based in PARIS (75013), this company of category PME shows in 2024 a revenue of 58 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-04-18
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2021 | 2020 | 2019 |
|---|---|---|---|---|
| Revenue | 57 900 € | 85 005 € | 49 811 € | 42 457 € |
| Net income | 12 674 € | 109 844 € | 97 241 € | 88 489 € |
| EBITDA | 8 290 € | 30 835 € | 11 347 € | -27 482 € |
| Net margin | 21.9% | 129.2% | 195.2% | 208.4% |
In 2024, FINANCIERE ELAVA PHARMA achieves revenue of 58 k€. Over the period 2019-2024, the company shows strong growth with a CAGR (compound annual growth rate) of +6.4%. Significant drop of -32% vs 2021. After deducting consumption (0 €), gross margin stands at 58 k€, i.e. a rate of 100%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 8 k€, representing 14.3% of revenue. Warning negative scissor effect: despite revenue change (-32%), EBITDA varies by -73%, reducing margin by 22.0 pts. This reflects costs rising faster than revenue. This level of operating margin is satisfactory for the sector. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 13 k€, i.e. 21.9% of revenue. This profit can be retained or distributed to shareholders.
57 900 €
57 900 €
8 290 €
8 280 €
12 674 €
14.3%
The debt ratio (= Financial debt / Equity x 100) stands at 4%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 95%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 5.5 years of cash flow to repay all financial debt. This ratio remains within usual banking standards. Cash flow represents 21.9% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. This high level provides strong self-financing capacity.
4.248%
94.857%
21.889%
5.523
In 2024, the debt ratio of FINANCIERE ELAVA PHARMA (4.25) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.
In 2024, the financial autonomy of FINANCIERE ELAVA PHARMA (94.9%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.
In 2024, the repayment capacity of FINANCIERE ELAVA PHARMA (5.52) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
The liquidity ratio (= Current assets / Current liabilities) stands at 1107.60. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
1107.603
0.0
In 2024, the liquidity ratio of FINANCIERE ELAVA PHARMA (1107.60) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.
In 2024, the interest coverage of FINANCIERE ELAVA PHARMA (0.0x) ranks above the median of the sector. This ratio indicates how many times operating income covers interest expenses. This comfortable position offers an appreciable safety margin.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 223 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 65 days. The gap of 158 days means the company finances its customers for over a month before being paid relative to supplier payments. This weighs on cash flow. Overall, WCR represents 180 days of revenue, i.e. 29 k€ to permanently finance.
29 014 €
223 j
65 j
0 j
180 j
Based on 103 transactions of similar company sales in 2024, the value of FINANCIERE ELAVA PHARMA is estimated at 51 514 € (range 14 991€ - 112 643€). With an EBITDA of 8 290€, the sector multiple of 5.0x is applied. The price/revenue ratio is 0.38x (conservative valuation). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Ajustez les pondérations selon votre analyse
This estimate is based on the analysis of 103 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare FINANCIERE ELAVA PHARMA with other companies in the same sector:
Voir toutes les statistiques du secteur Activités des sièges sociaux
The revenue of FINANCIERE ELAVA PHARMA in 2024 is 58 k€.
Yes, FINANCIERE ELAVA PHARMA generated a net profit of 13 k€ in 2024.
The headquarters of FINANCIERE ELAVA PHARMA is located in PARIS (75013), in the department Paris.
The tax return of FINANCIERE ELAVA PHARMA is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
FINANCIERE ELAVA PHARMA operates in the sector Activités des sièges sociaux (NAF code 70.10Z). See the 'Sector positioning' section above to compare the company with its competitors.